SCHEMBL5545658

SCHEMBL5545658

Nc1ccc(C(=O)c2ccc3ncccc3c2)cc1C(=O)c1cccc(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DOT1L Q8TEK3 1/20 0.60
FGFR1 P11362 2/20 0.50
FGFR2 P21802 2/20 0.50
FGFR3 P22607 2/20 0.50
SRC P12931 1/20 0.50
FGFR4 P22455 1/20 0.50
KDR P35968 1/20 0.50
PLK1 P53350 1/20 0.49
HDAC1 Q13547 1/20 0.48
HDAC2 Q92769 1/20 0.48
HTT P42858 3/20 0.46
ALOX15 P16050 2/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP3A4 P08684 1/20 0.42
CASP6 P55212 1/20 0.42
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545688 0.81 DOT1L (0.51) DOT1LFGFR1FGFR2FGFR3SRC
SCHEMBL27856105 0.79 DOT1L (0.73) DOT1LPLK1HDAC1HDAC2HTT
SCHEMBL6341269 0.76 RECQL (0.60) ALOX15KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL3550014 0.76 MAPT (0.58) HTTALOX15NPC1L3MBTL1ALDH1A1
SCHEMBL3559277 0.76 ALOX15 (0.51) ALOX15ALDH1A1TP53MAPTLMNA
SCHEMBL14339821 0.76 PKM (0.63) DOT1LL3MBTL1KDM4EALDH1A1LMNA
SCHEMBL15619322 0.75 MEN1 (0.50) DOT1LPLK1HDAC1HDAC2HTT
SCHEMBL18370043 0.75 DOT1L (0.64) DOT1LFGFR1FGFR2FGFR3SRC
SCHEMBL15619646 0.74 DOT1L (0.51) DOT1LPLK1HDAC1HDAC2HTT
SCHEMBL5548743 0.73 DOT1L (0.55) DOT1LPLK1HTTALOX15NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196094-B2 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-27 US disclosed
US-20030207887-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2003-11-06 US disclosed
EP-1322650-A2 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2003-07-02 EP disclosed
WO-2002024686-A2 FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207887-A1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives FNTA, FNTB, RCE1 DOT1L 1987/4885FGFR1 2838/4885FGFR2 4322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.